Certara Forms Strategic Alliance with Altasciences to Boost Early Drug Development
CERT sits 22% above its 52-week low of $5.19.
Summary
Certara, Inc. has announced a strategic partnership with Altasciences, a contract research organization, to accelerate early drug development. This collaboration is designed to integrate Certara's biosimulation and regulatory science solutions with Altasciences' preclinical and clinical research services. The partnership is a positive development, potentially expanding Certara's market reach and enhancing its service offerings, which could lead to increased client engagements and revenue in the competitive life sciences sector. Investors will be watching for further details on specific projects or financial contributions resulting from this alliance.
At the time of this announcement, CERT was trading at $6.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $959.8M. The 52-week trading range was $5.19 to $13.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.